Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7542627 | 0.81 | MAPK1 (0.38) | MAPK1GAANFKB1NFKB2RELA | |
| SCHEMBL9038834 | 0.81 | MAPK1 (0.38) | MAPK1GAANFKB1NFKB2RELA | |
| SCHEMBL2720348 | 0.79 | L3MBTL1 (0.50) | GAAL3MBTL1ALDH1A1 | |
| SCHEMBL27571076 | 0.78 | CCR2 (0.48) | L3MBTL1ALDH1A1 | |
| SCHEMBL29967266 | 0.76 | MAPK1 (0.42) | MAPK1GAANFKB1NFKB2RELA | |
| SCHEMBL6634675 | 0.74 | MAPK1 (0.38) | MAPK1GAAEPHX2NFKB1NFKB2 | |
| SCHEMBL9782199 | 0.73 | MAPT (0.47) | GAANAAAALDH1A1KDM4EMAPT | |
| SCHEMBL28009383 | 0.72 | MAPK1 (0.39) | MAPK1GAAEPHX2NFKB1NFKB2 | |
| SCHEMBL5576688 | 0.72 | EPHX2 (0.49) | MAPK1EPHX2RECQLALDH1A1 | |
| SCHEMBL1869892 | 0.72 | MAPK1 (0.34) | MAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903154-A | Preparation method of 1-oxo-6-azaspiro [3.3] heptane-6-carboxylic acid tert-butyl ester | 南京药石科技股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-107580595-B | Heterocyclic compounds and their use in the prevention or treatment of bacterial infections | 拜欧蒂姆公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111362852-A | Preparation method of drug intermediate 1-tert-butyloxycarbonyl-3-azetidinone | 浙江瑞博制药有限公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3292125-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2019-09-04 | — | — | EP | disclosed |
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2019-01-22 | — | — | US | disclosed |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2018-04-05 | — | — | US | disclosed |
| EP-3292125-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2018-03-14 | — | — | EP | disclosed |
| US-9790187-B2 | Heterocyclic compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-10-17 | — | — | US | disclosed |
| WO-2016177862-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2016-11-10 | — | — | WO | disclosed |
| EP-3091018-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2016-11-09 | — | — | EP | disclosed |
| CN-105541891-A | Baricitinib intermediate and preparation method thereof, and method for preparing baricitinib from intermediate | UNIV SOUTHEAST | 2016-05-04 | — | — | CN | disclosed |
| US-20150307455-A1 | HETEROCYCLIC COMPOUNDS | NATIONAL SCIENCE FOUNDATION | 2015-10-29 | — | — | US | disclosed |
| US-9102683-B2 | Heterocyclic compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130053553-A1 | HETEROCYCLIC COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, PEPD, LCT | MAPK1 3168/4885GAA 59/4885EPHX2 613/4885 |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | NQO1, PEPD, LCT | MAPK1 3168/4885GAA 59/4885EPHX2 613/4885 |
| US-20150307455-A1 | HETEROCYCLIC COMPOUNDS | CYP2C8, UGT1A8, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPK1 4579/4885GAA 535/4885EPHX2 268/4885 |
| US-20130053553-A1 | HETEROCYCLIC COMPOUNDS | CYP2C8, UGT1A8, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPK1 4579/4885GAA 535/4885EPHX2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.